Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters











Publication year range
1.
Cell Signal ; 89: 110170, 2022 01.
Article in English | MEDLINE | ID: mdl-34673141

ABSTRACT

Autophagy is a multi-step process regulated in part by AMP-activated protein kinase (AMPK). Phosphorylation of threonine 172 on the AMPK α-subunit enhances AMPK kinase activity, resulting in activation of downstream signaling. Integrin-mediated cell adhesion activates Src/ Focal Adhesion Kinase (FAK) signaling complex, which regulates multiple cellular processes including cell survival. We show here that Src signaling leads to direct phosphorylation of the AMPK-α subunit on a novel site, tyrosine 179, resulting in suppression of AMPK-T172 phosphorylation and autophagy upon integrin-mediated cell adhesion. By using chemical inhibitors, genetic cell models and targeted mutagenesis, we confirm an important role for Src and FAK in suppressing AMPK signaling and autophagy induced by various additional stimuli, including glucose starvation. Furthermore, we found that autophagy suppression by hydroxychloroquine promotes apoptosis in a cancer cell model that had been treated with Src inhibitors. Our findings reveal a link between the Src/ FAK complex and AMPK/ autophagy regulation, which may play an important role in the maintenance of normal cellular homeostasis and tumor progression.


Subject(s)
AMP-Activated Protein Kinases , src-Family Kinases , AMP-Activated Protein Kinases/metabolism , Autophagy , Cell Adhesion , Focal Adhesion Kinase 1/metabolism , Focal Adhesion Protein-Tyrosine Kinases/metabolism , Phosphorylation , src-Family Kinases/metabolism
2.
Sci Rep ; 10(1): 21653, 2020 12 10.
Article in English | MEDLINE | ID: mdl-33303850

ABSTRACT

In glaucoma, retinal ganglion cells degenerate progressively, leading to visual field loss and blindness. Presently, the only treatment strategy for glaucoma is lowering the intraocular pressure. However, there are cases in which patients develop progressive visual field loss even though their intraocular pressures are within normal ranges. Therefore, the development of novel therapeutic strategies is an urgent endeavor. Besides high intraocular pressure, several other factors have been proposed to be associated with glaucoma progression, e.g., myopia, blood flow impairment, and amyloid ß accumulation. We have previously reported that hop flower extracts possess γ-secretase inhibitory activities and reduce amyloid ß deposition in the brains of Alzheimer's disease model mice. In the current study, we showed that administration of hop flower extracts to glutamate-aspartate transporter (GLAST) knockout mice, the glaucoma model mice, attenuated glaucomatous retinal ganglion cell degeneration. Preservation of retinal ganglion cells in hop flower extract-administered mice was confirmed using optical coherence tomography, confocal scanning laser ophthalmoscopy, and retinal flatmount and histological evaluations. Hop flower extracts are, therefore, deemed a possible candidate as a novel therapeutic agent to treat glaucoma.


Subject(s)
Glaucoma/pathology , Humulus/chemistry , Plant Extracts/pharmacology , Retinal Ganglion Cells/drug effects , Animals , Disease Models, Animal , Mice , Mice, Knockout , Retinal Ganglion Cells/pathology , Tomography, Optical Coherence
3.
Sci Rep ; 9(1): 11519, 2019 08 08.
Article in English | MEDLINE | ID: mdl-31395936

ABSTRACT

Reduced adenosine triphosphate (ATP) levels in ischemic stroke constitute an upstream contributor to neuronal cell death. We have recently created a small chemical, named Kyoto University Substance 121 (KUS121), which can reduce cellular ATP consumption. In this study, we examined whether KUS121 has neuroprotective effects in rodent cerebral ischemia models. We evaluated cell viability and ATP levels in vitro after oxygen glucose deprivation (OGD) in rat cortical primary neuronal cultures incubated with or without KUS121. We found that KUS121 protected neurons from cell death under OGD by preventing ATP depletion. We also used in vivo ischemic stroke models of transient distal middle cerebral artery occlusion in C57BL/6 and B-17 mice. Administration of KUS121 in these models improved functional deficits and reduced brain infarction volume after transient focal cerebral ischemia in both C57BL/6 and B-17 mice. These results indicate that KUS121 could be a novel type of neuroprotective drug for ischemic stroke.


Subject(s)
Adenosine Triphosphate/metabolism , Brain Ischemia/prevention & control , Naphthalenes/pharmacology , Neuroprotective Agents/pharmacology , Pyridines/pharmacology , Stroke/prevention & control , Sulfonic Acids/pharmacology , Animals , Disease Models, Animal , Endoplasmic Reticulum Stress/drug effects , Infarction, Middle Cerebral Artery , Mice , Mice, Inbred C57BL , Naphthalenes/therapeutic use , Neurons/drug effects , Neurons/metabolism , Neuroprotective Agents/therapeutic use , Pyridines/therapeutic use , Reproducibility of Results , Sulfonic Acids/therapeutic use
4.
iScience ; 10: 211-221, 2018 Dec 21.
Article in English | MEDLINE | ID: mdl-30529953

ABSTRACT

Milk sugar is composed of glucose and galactose. Galactose is less suitable as an energy source than glucose. Thus, it has been a puzzle as to why mammals utilize galactose as a major component of milk sugar. Here we show that in hypoglycemic conditions, the presence of a trace amount of galactose, but not glucose, is able to maintain the production of mature glycoproteins and to abolish cell-death-inducing endoplasmic reticulum stress. In severely sugar-limited conditions, both glucose and galactose enter into the glycolytic pathway, but galactose is not able to raise the phosphofructokinase 1 activity, leading to the accumulation of fructose-6-phosphate, which in turn is utilized for the maturation of glycoproteins (e.g., growth factor receptors) and allows the activation of their intracellular signaling and prevents cell death from hypoglycemic conditions. Thus trace amounts of galactose may play unexpectedly important roles in the growth of infants and their protection during starvation.

5.
Cell Rep ; 21(9): 2628-2638, 2017 Nov 28.
Article in English | MEDLINE | ID: mdl-29186696

ABSTRACT

AMP-activated protein kinase (AMPK), a master regulator of cellular metabolism, is a potential target for type 2 diabetes. Although extensive in vitro studies have revealed the complex regulation of AMPK, much remains unknown about the regulation in vivo. We therefore developed transgenic mice expressing a highly sensitive fluorescence resonance energy transfer (FRET)-based biosensor for AMPK, called AMPKAR-EV. AMPKAR-EV allowed us to readily examine the role of LKB1, a canonical stimulator of AMPK, in drug-induced activation and inactivation of AMPK in vitro. In transgenic mice expressing AMPKAR-EV, the AMP analog AICAR activated AMPK in muscle. In contrast, the antidiabetic drug metformin activated AMPK in liver, highlighting the organ-specific action of AMPK stimulators. Moreover, we found that AMPK was activated primarily in fast-twitch muscle fibers after tetanic contraction and exercise. These observations suggest that the AMPKAR-EV mouse will pave a way to understanding the heterogeneous responses of AMPK among cell types in vivo.


Subject(s)
AMP-Activated Protein Kinases/metabolism , Biosensing Techniques/methods , Fluorescence Resonance Energy Transfer/methods , Animals , Female , Liver/metabolism , Male , Mice , Muscle, Skeletal/metabolism , Signal Transduction/genetics , Signal Transduction/physiology
6.
EBioMedicine ; 22: 225-241, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28780078

ABSTRACT

Parkinson's disease is assumed to be caused by mitochondrial dysfunction in the affected dopaminergic neurons in the brain. We have recently created small chemicals, KUSs (Kyoto University Substances), which can reduce cellular ATP consumption. By contrast, agonistic ligands of ERRs (estrogen receptor-related receptors) are expected to raise cellular ATP levels via enhancing ATP production. Here, we show that esculetin functions as an ERR agonist, and its addition to culture media enhances glycolysis and mitochondrial respiration, leading to elevated cellular ATP levels. Subsequently, we show the neuroprotective efficacies of KUSs, esculetin, and GSK4716 (an ERRγ agonist) against cell death in Parkinson's disease models. In the surviving neurons, ATP levels and expression levels of α-synuclein and CHOP (an ER stress-mediated cell death executor) were all rectified. We propose that maintenance of ATP levels, by inhibiting ATP consumption or enhancing ATP production, or both, would be a promising therapeutic strategy for Parkinson's disease.


Subject(s)
Adenosine Triphosphate/metabolism , Estrogens/administration & dosage , Parkinson Disease/drug therapy , Small Molecule Libraries/administration & dosage , Animals , Cell Death/drug effects , Culture Media , Disease Models, Animal , Estrogens/pharmacology , Glycolysis , Glycosides/administration & dosage , Glycosides/pharmacology , HEK293 Cells , Humans , Mice , Mitochondria/drug effects , Mitochondria/metabolism , PC12 Cells , Parkinson Disease/metabolism , Parkinson Disease/pathology , Pregnenolone/administration & dosage , Pregnenolone/analogs & derivatives , Pregnenolone/pharmacology , Rats , Small Molecule Libraries/pharmacology
7.
Methods Mol Biol ; 1567: 231-243, 2017.
Article in English | MEDLINE | ID: mdl-28276022

ABSTRACT

Genetically encoded biosensors utilizing the Förster resonance energy transfer (FRET) are powerful tools for live cell imaging of various cellular processes. Our group has previously developed a series of FRET-based biosensors, named "ATeam," for visualization of ATP levels inside a single living cell. ATeam not only provides a window of insight into a single cell but also allows for visualization of ATP levels in mitochondrial matrix of a single living cell. This novel tool is able to monitor alterations in cellular ATP in response to various treatments in real time. Here we present a method for the evaluation of ATP levels in mitochondria in living cells by using ATeam. At the end of this chapter, an example of experimental results is described for a better understanding of the presented procedure.


Subject(s)
Adenosine Triphosphate/analysis , Biosensing Techniques/methods , Fluorescence Resonance Energy Transfer/methods , Mitochondria/metabolism , Animals , Cells, Cultured , Fluorescence Resonance Energy Transfer/instrumentation , Humans , Image Processing, Computer-Assisted , Microscopy, Fluorescence , Molecular Imaging/instrumentation , Molecular Imaging/methods , Statistics as Topic
8.
Sci Rep ; 4: 5970, 2014 Aug 06.
Article in English | MEDLINE | ID: mdl-25096051

ABSTRACT

Neuroprotection may prevent or forestall the progression of incurable eye diseases, such as retinitis pigmentosa, one of the major causes of adult blindness. Decreased cellular ATP levels may contribute to the pathology of this eye disease and other neurodegenerative diseases. Here we describe small compounds (Kyoto University Substances, KUSs) that were developed to inhibit the ATPase activity of VCP (valosin-containing protein), the most abundant soluble ATPase in the cell. Surprisingly, KUSs did not significantly impair reported cellular functions of VCP but nonetheless suppressed the VCP-dependent decrease of cellular ATP levels. Moreover, KUSs, as well as exogenous ATP or ATP-producing compounds, e.g. methylpyruvate, suppressed endoplasmic reticulum stress, and demonstrably protected various types of cultured cells from death, including several types of retinal neuronal cells. We then examined their in vivo efficacies in rd10, a mouse model of retinitis pigmentosa. KUSs prevented photoreceptor cell death and preserved visual function. These results reveal an unexpected, crucial role of ATP consumption by VCP in determining cell fate in this pathological context, and point to a promising new neuroprotective strategy for currently incurable retinitis pigmentosa.


Subject(s)
Adenosine Triphosphatases/antagonists & inhibitors , Cell Cycle Proteins/antagonists & inhibitors , Enzyme Inhibitors/pharmacology , Neuroprotective Agents/pharmacology , Retinal Pigment Epithelium/drug effects , Retinitis Pigmentosa/drug therapy , Small Molecule Libraries/pharmacology , Adenosine Triphosphatases/genetics , Adenosine Triphosphatases/metabolism , Adenosine Triphosphate/agonists , Adenosine Triphosphate/metabolism , Animals , Cell Cycle Proteins/genetics , Cell Cycle Proteins/metabolism , Disease Models, Animal , Endoplasmic Reticulum Stress/drug effects , Endoplasmic Reticulum Stress/genetics , Enzyme Inhibitors/chemical synthesis , Gene Expression , HEK293 Cells , HeLa Cells , Humans , Mice , Neuroprotective Agents/chemical synthesis , PC12 Cells , Pyruvates/pharmacology , Rats , Retinal Pigment Epithelium/metabolism , Retinal Pigment Epithelium/pathology , Retinitis Pigmentosa/genetics , Retinitis Pigmentosa/metabolism , Retinitis Pigmentosa/pathology , Small Molecule Libraries/chemical synthesis , Valosin Containing Protein
9.
PLoS One ; 9(1): e87185, 2014.
Article in English | MEDLINE | ID: mdl-24489866

ABSTRACT

Coincident with the expanding population of aged people, the incidence of Alzheimer disease (AD) is rapidly increasing in most advanced countries. At present, no effective prophylactics are available. Among several pathological mechanisms proposed for AD, the "amyloid hypothesis" has been most widely accepted, in which accumulation or deposition of Aß is considered to be the initial event. Thus, prevention of Aß production would be an ideal strategy for the treatment or prevention of AD. Aß is produced via the proteolytic cleavage of its precursor protein, APP (amyloid precursor protein), by two different enzymes, ß and γ-secretases. Indeed, inhibitors against either or both enzymes have been developed and tested for clinical efficacy. Based on the "amyloid hypothesis", we developed a luciferase-based screening method to monitor γ-secretase activity, screened more than 1,600 plant extracts, most of which have long been used in Chinese medicine, and observed that Hop extracts significantly inhibit Aß production in cultured cells. A major component of the inhibitory activity was purified, and its chemical identity was determined by NMR to be Garcinielliptone HC. In vivo, oral administration of Hop extracts to AD model mice decreased Aß depositions in the cerebral cortex of the parietal lobe, hippocampus, and artery walls (amyloid angiopathy) in the brains. In a Morris water maze test, AD model mice that had daily consumed Hop extracts in their drinking water showed significant mitigation of memory impairment at ages of 9 and 12 months. Moreover, in the open field test oral administration of Hop extracts also prevented an emotional disturbance that appeared in the AD mice at 18 months. Despite lifelong consumption of Hop extracts, no deleterious side effects were observed at any age. These results support the "amyloid hypothesis", and indicate that Hop extract is a promising candidate for an effective prophylactic for AD.


Subject(s)
Alzheimer Disease/drug therapy , Plant Extracts/administration & dosage , Sesterterpenes/administration & dosage , Administration, Oral , Alzheimer Disease/metabolism , Alzheimer Disease/psychology , Amyloid Precursor Protein Secretases/antagonists & inhibitors , Amyloid Precursor Protein Secretases/metabolism , Amyloid beta-Peptides/metabolism , Animals , HEK293 Cells , Humans , Humulus/chemistry , Maze Learning/drug effects , Memory/drug effects , Mice , Mice, Inbred C57BL , Mice, Transgenic , Phenotype , Plant Extracts/chemistry , Plant Extracts/isolation & purification , Sesterterpenes/chemistry , Sesterterpenes/isolation & purification
10.
PLoS One ; 8(2): e56012, 2013.
Article in English | MEDLINE | ID: mdl-23457492

ABSTRACT

Catalase is a key antioxidant enzyme that catalyzes the decomposition of hydrogen peroxide (H2O2) to water and oxygen, and it appears to shuttle between the cytoplasm and peroxisome via unknown mechanisms. Valosin-containing protein (VCP) belongs to the AAA class of ATPases and is involved in diverse cellular functions, e.g. cell cycle and protein degradation, etc. Here we show that VCP and PEX19, a protein essential for peroxisome biogenesis, interact with each other. Knockdown of either VCP or PEX19 resulted in a predominantly cytoplasmic redistribution of catalase, and loss of VCP ATPase activity also increased its cytoplasmic redistribution. Moreover, VCP knockdown decreased intracellular ROS levels in normal and H2O2-treated cells, and an oxidation-resistant VCP impaired the ROS-induced cytoplasmic redistribution of catalase. These observations reveal a novel feedback mechanism, in which VCP can sense H2O2 levels, and regulates them by controlling the localization of catalase.


Subject(s)
Adenosine Triphosphatases/metabolism , Catalase/analysis , Catalase/metabolism , Cell Cycle Proteins/metabolism , Cytoplasm/metabolism , Hydrogen Peroxide/metabolism , Membrane Proteins/metabolism , Adenosine Triphosphatases/genetics , Cell Cycle Proteins/genetics , Gene Knockdown Techniques , HeLa Cells , Humans , Membrane Proteins/genetics , RNA, Small Interfering/genetics , Reactive Oxygen Species/metabolism , Up-Regulation , Valosin Containing Protein
SELECTION OF CITATIONS
SEARCH DETAIL